Eris Lifesciences Ltd (NSE: ERIS, BSE: 540596) is a Ahmedabad, Gujarat-based company in the Pharmaceuticals industry. With a market capitalisation of ₹15,877 Cr, it ranks #431 by market cap among the 6,137 Indian listed companies on FinBizNet, and #8 of 63 in Pharmaceuticals. At ₹1,095.50 (as of 25 Oct 2026), the share price is 37.0% below its 52-week high of ₹1,740.00 and 0.7% above its 52-week low of ₹1,087.90. The share price is down 30.8% over one year and down 21.8% over three months.
| Current Price | ₹1,095.50 |
|---|---|
| Market Cap | ₹15,877 Cr |
| NSE Symbol | ERIS |
| BSE Code | 540596 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Pharmaceuticals |
| P/E Ratio | 24.8 |
| Return on Equity | 18.07% |
| Return on Assets | 7.30% |
| 52-Week Range | ₹1,087.90 – ₹1,740.00 |
| 1-Year Price Change | -30.8% |
| 3-Month Price Change | -21.8% |
| Beta (1Y) | 0.06 |
| Dividend Yield | 1.29% |
| Headquarters | Ahmedabad, Gujarat |
| Website | www.eris.co.in |
| Revenue | ₹873 Cr |
|---|---|
| Net Profit | ₹144 Cr |
| Net Margin | 16.5% |
| EPS (Basic) | ₹10.28 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Eris Lifesciences Limited, together with its subsidiaries, provides domestic branded formulations for chronic and sub-chronic therapies in India and internationally. The company offers various branded formulations in various therapeutic areas, such as anti–diabetes, cardiovascular, nutrition, dermatology, neuroscience, gynecology, nephrology, and oncology, as well as central nervous system, women’s health, and vitamins/minerals/nutrients. It also provides patient care services, including ambulatory blood pressure measurement, ambulatory electrocardiogram measurement, continuous glucose monitoring system, sleep study, and anti-natal care solutions. It offers its products through wholesale drug distributors, stockists, retail and e-commerce pharmacies. Eris Lifesciences Limited was incorporated in 2007 and is headquartered in Ahmedabad, India.
1. Pharmaceuticals-This segment develops, manufactures, and commercializes pharmaceutical products in chronic and acute therapeutic areas.
1. Pharmaceuticals-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Abbott India Ltd. | ₹55,577 Cr | 35.5 | 34.46% | ₹1,814 Cr | -16.1% |
| Ajanta Pharma Limited | ₹41,591 Cr | 39 | 25.39% | ₹1,626 Cr | +36.3% |
| Emcure Pharmaceuticals Ltd | ₹34,533 Cr | 36.3 | 19.57% | ₹2,580 Cr | +31.1% |
| Piramal Pharma Ltd | ₹26,284 Cr | -79 | -4.00% | ₹2,270 Cr | -1.6% |
| RUBICON RESEARCH LIMITED | ₹24,972 Cr | 97.6 | 19.14% | ₹534 Cr | — |
| Caplin Point Laboratories Ltdte | ₹17,484 Cr | 26.9 | 19.94% | ₹610 Cr | +10.3% |
| Pfizer Ltd. | ₹17,448 Cr | 24.1 | 17.16% | ₹653 Cr | -32.1% |
| Eris Lifesciences Ltd | ₹15,877 Cr | 24.8 | 18.07% | ₹873 Cr | -30.8% |
| Astrazeneca Pharma India Ltd. | ₹14,915 Cr | 80.6 | 22.82% | ₹683 Cr | -34.5% |
Listed by market capitalisation. Ratios are shown for context only.
Eris Lifesciences Ltd is trading at ₹1,095.50, with a market capitalisation of ₹15,877 Cr.
Eris Lifesciences Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Pharmaceuticals).
Eris Lifesciences Ltd has a P/E of 24.8 and a return on equity of 18.07%.
Eris Lifesciences Ltd is listed on the NSE under the symbol ERIS and on the BSE under the scrip code 540596.
Eris Lifesciences Ltd's share price is down 30.8% over one year and down 21.8% over three months. Its 52-week range is ₹1,087.90 to ₹1,740.00.
In Q1 FY27, Eris Lifesciences Ltd reported revenue of ₹873 Cr and net profit of ₹144 Cr, with basic EPS of ₹10.28 (consolidated, parsed from the company's exchange filing).
Data as of 25 Oct 2026. Descriptive market data only — not investment advice.